AI job interviews, menstrual organoids, Fujitsu’s mainframe exit: the tech shifts reshaping Britain

The UK’s innovation paradox: progress at what cost?

Britain’s tech sector is caught in a bind. On one side, breakthroughs promise to revolutionise medicine, hiring, and computing. On the other, these same advances expose gaping ethical and practical flaws—often at the expense of the public they’re meant to serve. This week’s developments aren’t just about innovation; they’re about who benefits, who’s left behind, and whether the UK can afford to keep chasing progress without guardrails.

AI job interviews: efficiency or exploitation?

Nearly half of UK job seekers have now faced an AI interview, according to Greenhouse’s survey. The numbers tell a story of a hiring process stripped of humanity: 30% of candidates have walked away from roles because of it. The complaints are damning—awkward pauses, robotic feedback, and a sense that employers are outsourcing not just screening, but empathy itself.

This isn’t just about bad user experience. It’s about power. AI interviews favour candidates who can game algorithms—those with the time, resources, and cultural capital to perform for a machine. Meanwhile, employers hide behind "efficiency," ignoring the fact that hiring is a two-way street. If a company can’t be bothered to meet its applicants, why should talent bother with them?

The UK’s AI hiring boom isn’t just a tech trend; it’s a symptom of a labour market where workers are increasingly seen as data points, not people. And with no regulation in sight, the question isn’t whether AI will replace human recruiters—it’s whether it already has, and what we’ve lost in the process.

Menstrual organoids: science’s quiet revolution

In a lab, a tiny piece of tissue is shedding light on one of medicine’s most neglected mysteries: how the uterus repairs itself every month without scarring. Researchers have grown the first organoid capable of menstruation, offering insights into conditions like endometriosis—a disease that still takes an average of eight years to diagnose in the UK.

This isn’t just a scientific curiosity. It’s a rebuke to decades of underfunding in women’s health research. The fact that we’re only now understanding how the uterine lining regenerates—despite menstruation being a universal experience for half the population—speaks volumes about where medical priorities have lain. The UK’s endometriosis crisis isn’t just a diagnostic failure; it’s a research failure. And this organoid could be the first step toward fixing it.

But don’t expect overnight change. Breakthroughs like this take years to translate into treatments, and in a system already stretched thin by NHS cuts and post-Brexit funding gaps, there’s no guarantee this research will make it to patients. The question isn’t whether the science is groundbreaking—it is. The question is whether the UK’s healthcare infrastructure can keep up.

Fujitsu’s mainframe exit: the end of an era, or a missed opportunity?

Fujitsu has confirmed what many in the tech world already knew: its mainframe business will be dead by 2035. The announcement might seem niche, but it’s a canary in the coal mine for Britain’s digital future.

Mainframes still power critical infrastructure—banks, government systems, airlines. Fujitsu’s phase-out leaves the UK with a dilemma: modernise now, or risk falling behind. The company is betting on quantum and AI supercomputers, but the transition won’t be seamless. Already, the UK’s tech infrastructure is creaking under the weight of underinvestment. The Post Office scandal, driven by Fujitsu’s faulty Horizon system, is a stark reminder of what happens when legacy tech fails—and who pays the price.

Fujitsu’s pivot also raises uncomfortable questions about defence. The company is in talks with the UK, Japan, and Australia on "tech that contributes to global stability." But what does that mean? More surveillance? More AI-driven warfare? The lack of transparency is troubling. If the UK is going to stake its future on quantum and AI, it needs more than vague promises—it needs oversight, accountability, and a plan that doesn’t repeat the mistakes of the past.

Hay fever and the climate crisis: when nature becomes the enemy

The European pollen season is now two weeks longer than it was in the 1990s. For the millions of Britons suffering from hay fever, this isn’t just an inconvenience—it’s a public health crisis in slow motion. The climate emergency isn’t just melting ice caps; it’s making everyday life unbearable for those with allergies, asthma, and respiratory conditions.

This is the quiet cost of inaction. While politicians debate net-zero targets, people are already paying the price—literally. Hay fever treatments cost the NHS millions annually, and that’s before factoring in lost productivity. The UK’s greenwashing problem isn’t just about corporate PR; it’s about a government that talks big on climate while failing to prepare for its most immediate consequences.

The irony? Nature was supposed to be the antidote to modern life. Now, thanks to decades of environmental neglect, it’s becoming another source of stress. The question isn’t whether the UK can adapt—it’s whether it will, before the damage becomes irreversible.

What’s really at stake?

This week’s innovations aren’t just about tech or science—they’re about power. Who controls AI hiring? Who funds women’s health research? Who decides how we transition away from legacy systems? And who pays the price when nature turns against us?

The UK is at a crossroads. It can either double down on innovation without safeguards, or it can demand that progress serve the public, not just the bottom line. The choice isn’t between stagnation and advancement—it’s between a future where technology works for everyone, and one where it leaves more people behind. So far, the signs aren’t promising.